CD8A and cancer: DEXAFP-treated HCC mice presented significantly more gamma interferon-expressing CD8+ T lymphocytes and augmented the concentrations of IFN-gamma and interleukin-2, with reduced CD25+/Foxp3+ regulatory T cells and reduced concentrations of interleukin-10 and transforming growth factor-beta in the cancer microenvironment.